Publication:
Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients

Thumbnail Image
Files
Cruzado,.pdf (619.96 KB)
Official URL
http://dx.doi.org/10.1007/s00520-014-2147-x
Full text at PDC
Publication Date
2014
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Google Scholar
Exportar
DC QDC MarcXML RDF MODS METS ORE-ATOM
Research Projects
Organizational Units
Journal Issue
Abstract
BACKGROUND: Chemotherapy can induce cognitive impairment in cancer patients. The main goal of this longitudinal study was to determine the incidence, characteristics, and duration of cognitive dysfunction in patients treated with adjuvant chemotherapy for colon cancer. PATIENTS AND METHODS: We assessed cognitive function, quality of life, anxiety and depression, fatigue, and hemoglobin levels in colon cancer patients at three assessment points: pre-chemotherapy (n=81), post-chemotherapy (n=73), and after 6-month follow-up (n=54). All patients were treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) for 6 months. RESULTS: Thirty patients (37%) had cognitive impairment in the pre-chemotherapy evaluation, mainly in processing speed and psychomotor executive function (Trail Making Test A and B). At the end of treatment, the main domain affected was the verbal memory, with an acute decline detected in 56% of patients. Fifty-four percent of the patients improved their dysfunction after 6 months of follow-up, whereas 18 (33%) of them showed worsening in at least one test. Cognitive impairment was most common in older patients and in those with less years of education. Quality of life, anxiety, depression, fatigue, and hemoglobin did not influence the results of the cognitive tests. CONCLUSIONS: Adjuvant FOLFOX4 in patients with colon cancer can have a negative effect on verbal memory. This deterioration is usually mild and transient.
Description
UCM subjects
Oncología , Psicología clínica y psicodiagnóstico
Unesco subjects
3201.01 Oncología , 6101 Patología
Keywords
Citation
Argyriou AA, Assimakopoulos K, Iconomou G et al (2011) Either called “chemobrain” or “chemofog”, the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage 41:126–139. doi:10.1016/j.jpainsymman.2010.04.021 CrossRef Janelsins MC, Kohli S, Mohile SG et al (2011) An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 20(38):431–438. doi:10.1053/j.seminoncol.2011.03.014 CrossRef Ahles TA, Saykin AJ, Furstenberg CT et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493. doi:10.1200/JCO.20.2.485 PubMedCrossRef Wefel JS, Lenzi R, Theriault RL et al (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299. doi:10.1002/cncr.20272 PubMedCrossRef Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116:113–123. doi:10.1007/s10549-008-0211-2 PubMedCrossRef Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348–3356. doi:10.1002/cncr.25098 PubMedCrossRef Phillips KM, Jim HS, Small BJ et al (2012) Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer 118:1925–1932. doi:10.1002/cncr.26432 PubMedCentralPubMedCrossRef Koppelmans V, Breteler MM, Boogerd W et al (2012) Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 30:1080–1086. doi:10.1200/JCO.2011.37.0189 PubMedCrossRef Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25:2455–2463. doi:10.1200/JCO.2006.08.1604 PubMedCrossRef Wefel JS, Schagen SB (2012) Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 12:267–275. doi:10.1007/s11910-012-0264-9 PubMedCrossRef Jansen CE, Miaskowski C, Dodd M et al (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104:2222–2223. doi:10.1002/cncr.21469 PubMedCrossRef Falleti MG, Sanfilippo A, Maruff P et al (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59:60–70. doi:10.1016/j.bandc.2005.05.001 PubMedCrossRef Stewart A, Bielajew C, Collins B et al (2006) (2006). A metaanalysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 20:76–89. doi:10.1080/138540491005875 PubMedCrossRef Jim HS, Phillips KM, Chait S et al (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578–3587. doi:10.1200/JCO.2011.39.5640 PubMedCentralPubMedCrossRef Boykoff N, Moieni M, Subramanian SK (2009) (2009). Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3:223–232. doi:10.1007/s11764-009-0098-x PubMedCentralPubMedCrossRef Ahles TA, Saykin AJ, McDonald BC et al (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434–4440. doi:10.1200/JCO.2009.27.0827 PubMedCentralPubMedCrossRef Schagen SB, Muller MJ, Boogerd W et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387–1397. doi:10.1093/annonc/mdf241 PubMedCrossRef Vearncombe KJ, Rolfe M, Wright M et al (2009) Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 15:951–962. doi:10.1017/S1355617709990567 PubMed Jenkins V, Shilling V, Deutsch G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834. doi:10.1038/sj.bjc.6603029 PubMedCentralPubMedCrossRef Hermelink K, Untch M, Lux MP et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109:1905–1913. doi:10.1002/cncr.22610 PubMedCrossRef Jim HS, Donovan KA, Small BJ et al (2009) Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115:776–783. doi:10.1002/cncr.24192 CrossRef Wefel J, Vardy J, Ahles T, Schagen S (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708. doi:10.1016/S1470-2045(10)70294-1 PubMedCrossRef Peña-Casanova J (2005) Test de Barcelona-Revisado. Programa Integrado de Exploración Neuropsicológica. Elsevier- Masson, Barcelona Reitan RM, Olfson D (1985) The Halstead–Reitan Neuropsychological Test Battery: therapy and clinical interpretation. Neuropsychological Press, Tucson 25. Tombaugh TN (2004) Trail making test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19:203–214. doi:10.1016/S0887-6177(03)00039-8 Wechsler D (2001) Escala de Inteligencia para adultos, 3ª versión. TEA, Madrid Golden CJ (2005) Stroop, Test de Colores y Palabras. TEA, Madrid Fayers P, Bottomley A, EORTC Quality of Life Group; Quality of Life Unit (2002) Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38(Suppl 4):S125–S133. doi:10.1016/S0959-8049(01)00448-8 PubMedCrossRef Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370. doi:10.1111/j.1600-0447.1983.tb09716.x PubMedCrossRef Mendoza TR, Wang XS, Cleeland CS et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85:1186–1196. doi:10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N PubMedCrossRef Crawford JR, Garthwaite PH, Gault CB (2007) Estimating the percentage of the population with abnormally low scores (or abnormally large score differences) on standardized neuropsychological test batteries: a generic method with applications. Neuropsychology 21:419–430. doi:10.1037/0894-4105.21.4.419 PubMedCrossRef Chelune GJ, Naugle RI, Luders H et al (1993) Individual change after epilepsy surgery: practice effects and base-rate information. Neuropsychology 7:41–52. doi:10.1037//0894-4105.7.1.41 CrossRef Quintana M, Peña-Casanova J, Sánchez-Benavides G et al (2011) Spanish multicenter normative studies (Neuronorma project): norms for the abbreviated Barcelona test. Arch Clin Neuropsychol 26:144–157. doi:10.1093/arclin/acq098 PubMedCrossRef García A, Fernández M, Blesa R et al (2012) Using artificial neural networks in clinical neuropsychology: high performance in mild cognitive impairment and Alzheimer’s disease. Exp Neuropsychol 34:195–208. doi:10.1080/13803395.2011.630651 CrossRef Molinuevo JL, Gómez-Anson B, Monte GC et al (2011) Neuropsychological profile of prodromal Alzheimer’s disease (Prd-AD) and their radiological correlates. Arch Gerontol Geriatr 52:190–196. doi:10.1016/j.archger.2010.03.016 PubMedCrossRef Lezak MD, Howieson DB, Bigler ED et al (2012) Neuropsychological assessment, 5th edn. Oxford University Press, New York Vardy JL, Dhillon H, Xu W, et al. (2009). Cognitive function and fatigue in colorectal cancer (CRC) patients: baseline assessments prior to chemotherapy. J Clin Oncol 27:15 s (Suppl; abstract 9557). WefelJS, Vidrine DJ, Veramonti TL et al (2011) Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 117:190–196. doi:10.1002/cncr.25298 PubMedCrossRef Benveniste H, Zhang S, Reinsel RA et al (2012) (2012). Brain metabolomic profiles of lung cancer patients prior to treatment characterized by proton magnetic resonance spectroscopy. Int J Clin Exp Med 5:154–164 PubMedCentralPubMed Andreis F, Ferri M, Mazzocchi M et al (2013) (2013). Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study. Support Care Cancer 21:583–590. doi:10.1007/s00520-012-1560-2 PubMedCrossRef Mancuso A, Migliorino M, De Santis S et al (2006) Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 17:146–150. doi:10.1093/annonc/mdj038 PubMedCrossRef Hang R, Yang YM, Dietrich J et al (2008) Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7:12. doi:10.1186/jbiol69 CrossRef Sharpe MJ, Fardell JE, Vardy J, Johnston IN (2012) The chemotherapy agent oxaliplatin impairs the renewal of fear to an extinguished conditioned stimulus in rats. Behav Brain Res 227:295–299. doi:10.1016/j.bbr.2011.11.005 PubMedCrossRef Fardell JE, Vardy J, Shah JD, Johnston IN (2012) Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychophar-macology (Berl) 220:183–193. doi:10.1007/s00213-011-2466-2
URI
https://hdl.handle.net/20.500.14352/35199
Collections
Artículos